Scancell : Interim Report 31st October 2023

CHIEF EXECUTIVE OFFICER'S STATEMENT


I am pleased to report the Group's interim results for the six-month period ended 31 October 2023. During the period, Scancell...

Related Keywords

United Kingdom ,Lindy Durrant ,Scancell Moditope ,Scancell Avidimab ,Scancell Immunobody ,Company Moditope ,Scancell Holdings ,Registrar Of Companies ,European Union ,Convertible Loan Notes ,Financial Position ,Derivative Liabilities ,Consolidated Profit ,Consolidated Cash Flow Statement ,Convertible Loan ,Interim Financial Statements ,Companies Act ,Period Restatement ,Annual Report ,Open Offer ,